drugset / Trial / NCT03773562

Imaging the Migraine Brain Pre- and Post-Erenumab

NCT03773562

Phase 4 Completed 50 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging (MRI).

Timeline

Start
2019-03-25
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 140 mg Subcutaneous

Indications